{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-064580","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.063640+00:00","generated_at":"2026-06-18T08:14:15.667535+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Alnylam expands board to 13, elects Peter N. Kellogg as Class II director","bullets":["Board expanded from 12 to 13 directors; Kellogg fills new vacancy effective March 7, 2023.","Kellogg will serve as Class II director until 2024 annual meeting and is expected to join the Audit Committee.","Non-employee director cash fee $55,000 (rising to $60,000 April 1, 2023); stock option for 4,948 shares at $194.34 strike.","Option vests ratably over three years; annual equity awards begin 2024 with $400,000 grant-date value.","Indemnification agreement entered with the Company consistent with other non-employee directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-064580","json":"https://secwatch.observer/filing/0001193125-23-064580.json","markdown":"https://secwatch.observer/filing/0001193125-23-064580.md","text":"https://secwatch.observer/filing/0001193125-23-064580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523064580/0001193125-23-064580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523064580/d481911d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:14:15.667535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15f393d5ca","claim":"Peter N. Kellogg was elected as Director at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"Effective as of March 7, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from twelve to thirteen and elected Peter N. Kellogg to fill the newly created vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523064580/0001193125-23-064580-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}